AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03236883 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: GPBSC
Description: immunotherapy :GPBSC were collected from donor .Cells were infused to the patients in 4 week,at a dose of (2-3)\*10\^8/kg,once a month,repeated every 4weeks,three times in all.
Study NCT00797303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months
Study NCT00321932 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: calcium
Description: All randomized patients (control and study drug) will take 1000 mg of calcium and 400 - 500 International Units (IU) of vitamin D orally each day, beginning as soon as possible after study enrollment. These supplements may be taken either in the morning or in the evening with food. Participants will continue taking the supplements on a daily basis until the final study visit (approximately 12 months after the transplant date).
Study NCT00321932 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium
Description: All randomized patients (control and study drug) will take 1000 mg of calcium and 400 - 500 International Units (IU) of vitamin D orally each day, beginning as soon as possible after study enrollment. These supplements may be taken either in the morning or in the evening with food. Participants will continue taking the supplements on a daily basis until the final study visit (approximately 12 months after the transplant date).
Study NCT00321932 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: Given orally
Study NCT04428320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic floor injection
Description: Injection of 10 cc of bupivacaine
Study NCT03462199 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Actazin (green kiwi powder) High Dose
Description: Participants will consume 4 capsules (600 mg green kiwi powder) daily for 28-days
Study NCT03462199 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Actazin (green kiwi powder) Low Dose
Description: Participants will consume 4 capsules (150 mg green kiwi powder) daily for 28-days
Study NCT03462199 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control Formula (Actazin green kiwi powder + PreticX prebiotic)
Description: Participants will consume 4 capsules (150 mg green kiwi powder + 250 mg PreticX prebiotic) daily for 28-days
Study NCT03462199 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Livaux (gold kiwi powder) High Dose
Description: Participants will consume 4 capsules (600 mg gold kiwi powder) daily for 28-days
Study NCT03462199 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Livaux (gold kiwi powder) Low Dose
Description: Participants will consume 4 capsules (150 mg gold kiwi powder) daily for 28-days
Study NCT03462199 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Description: Participants will consume 4 capsules containing no active ingredients daily for 28-days
Study NCT01194258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Study NCT01194258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Study NCT01194258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human hyaluronidase PH20
Study NCT01194258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Study NCT00321932 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: Given orally
Study NCT00321932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Zoledronic acid (Zometa®) will be administered after randomization (but within 28 days prior to transplant) and at 3 and 6 months after the transplant for a total of 3 doses. The dose of Zometa will be 4 mg intravenous in 100 ml of sterile 0.9% sodium chloride, United States Pharmacopeia (USP), or 5% dextrose, USP infused over a minimum of 15 minutes for patients with a calculated creatinine clearance of ≥60 mL/min. The drug may be administered through a peripheral or a central intravenous line.
Study NCT05787041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-fat diet group（AD16 20mg）
Description: AD16 was administered with 240 mL water 30 minutes after the subjects ate a high-fat, high-calorie food.
Study NCT05787041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fasted group（AD16 20mg）
Description: Subjects took AD16 on an empty stomach and fasted within 4 hours after taking the drug.
Study NCT04431063 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal Stump Suturing
Description: in ACL Reconstruction case , Group A consist of subject with operation procedure suturing the distal stump peroneus longus against the peroneus brevis in ACL reconstruction using the peroneus longus autograft.
Study NCT00619736 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01194258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Study NCT00197236 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix™
Description: 2 intramuscular injections, 6 months apart
Study NCT00197236 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix™
Description: 2 intramuscular injections, 6 months apart
Study NCT00197236 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™
Description: 1 intramuscular injection
Study NCT00197236 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix™
Description: 1 intramuscular injection
Study NCT00197236 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ActHIB™
Description: 1 intramuscular injection
Study NCT00197236 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ActHIB™
Description: 1 intramuscular injection
Study NCT01846169 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food deliveries
Description: Frequency of food deliveries is based on level of food insecurity at baseline (i.e., more food insecurity receives more frequent food deliveries). Deliveries are tailored to the diet of the client (e.g., consist of soft foods if participant has trouble chewing; has more fruits and vegetables if that was a food category the participant at less of at baseline). The brief nutrition education is a review of basic nutrition concepts and healthy eating ideas.
Study NCT00362206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate/Simvastatin
Description: Combination of Fenofibrate and Simvastatin 20mg
Study NCT00362206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate/Simvastatin
Description: Combination of Fenofibrate and Simvastatin 40 mg
Study NCT00362206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: Pravastatin 40 mg
Study NCT00383188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Capsule, once daily (QD) for 12 weeks
Study NCT00383188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Capsule, 0.5 mg of PH-797804, once daily (QD) for 12 weeks
Study NCT00383188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Capsule, 3 mg of PH-797804, once daily (QD) for 12 weeks
Study NCT02150824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004
Description: BI 187004 high dose once daily
Study NCT00383188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Capsule, 6 mg of PH-797804, once daily (QD) for 12 weeks
Study NCT00383188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Capsule, 10 mg of PH-797804, once daily (QD) for 12 weeks
Study NCT01076335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Hormonal Therapy
Description: Monthly or quarterly LHRH Agonist Depot injection (leuprolide or goserelin acetate) for one year.
Study NCT01076335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 35 mg/m2 by vein (IV) on Day 1, 8, 15 and 22 every 6 weeks.
Study NCT03987763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-122 Lotion
Description: Topical
Study NCT04013698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP level 5 cmH2O
Description: PEEP level set for 45 minutes
Study NCT04013698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP level 15 cmH2O
Description: PEEP level set for 45 minutes
Study NCT03573817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revefenacin
Description: Revefenacin is administered via a nebulizer.
Study NCT03573817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo version of Revefenacin is administered via a nebulizer.
Study NCT03573817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Formoterol
Description: Administered sequentially in both revefenacin and placebo arms using a nebulizer.
Study NCT03573817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: Administered sequentially in both revefenacin and placebo arms using a nebulizer.
Study NCT02142231 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Sterile Acupuncture Needles (Seirin (R) 0.15x0.2) will be used, Needles are inserted for approx. 0.5-1 cm until deqi response is elicited
Study NCT02142231 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Laser Acupuncture
Description: Therefore a laser irradiation is faked, approaching a nonfunctioning laser pen, which has been deactivated by the manufacturer (3B Scientific GmbH, Hamburg, Germany). Only red light is emitted. To further emphasize the imaginary power of this sham procedure, visual and acoustic signals accompany the red light emission. Patients are treated at the same acupuncture points as in the acupuncture group for one minute without skin contact. The resting time after treatment is 18 minutes.
Study NCT02379234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulation
Description: Nurses received, in addition to the conventional formation (as in the control arm), a set of 3 high-fidelity simulation sessions. Each session lasted 1 to 2 hours, used high fidelity mannequin and CVVH generator and took place in an ICU room environment. For each session, a specific scenario was designed, the session began with a briefing and ended with a debriefing, based on video recording.
Study NCT01830361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midostaurin (PKC412)
Description: Midostaurin 50 mg (2 capsules) twice daily days 8-21 in induction II + consolidation I-III; maintenance treatment twice daily continuously for 12 months
Study NCT01574222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cell adenovirus CCL21 vaccine
Description: Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling.
Study NCT04202562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ab interno trabeculectomy
Description: Ab interno trabeculectomy performed after pupil contraction and 90 degrees ablation of the nasal trabecular meshwork
Study NCT04202562 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract
Description: Cataract surgery with minimal clear cornea incision and phacoemulsification
Study NCT04202562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract
Description: Cataract surgery with minimal clear cornea incision and phacoemulsification
Study NCT01598857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blisibimod
Study NCT01598857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02038296 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transarterial chemoembolization
Study NCT04442958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Convalescent Immune Plasma
Description: One dose of 200 mL of convalescent ımmune plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to standart critical care treatment.
Study NCT01630109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: A one time dose of either Metoclopramide 5 mg or 10 mg (or placebo) given orally 30 minutes prior to pill capsule endoscopy.
Study NCT01630109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo capsule made to look like the metoclopramide capsule.
Study NCT02778516 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Restriction
Study NCT02491073 — intervention group
Intervention type: OTHER
Intervention: blood draw
Description: Investigate the possibility of assay artifacts impacting the measurement of thyroid hormones, in particular FT4 and FT3, in ESL treated subjects compared to non-ESL-treated subjects.
Study NCT06222372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: antibiotic
Study NCT01152333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin-(9-39) Acetate
Description: Exendin (9-39) will be diluted in saline 0.9% and administered through IV infusion once for a maximum of 2.5 hours in length.
Study NCT01152333 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: Saline will be administered through IV infusion once for a maximum of 2.5 hours in length
Study NCT02739022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Psychological Support for the Critically Ill (EPSCI)
Description: early psychological support based on positive therapeutic suggestion
Study NCT03454347 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Profile Perform
Description: The dietary supplement includes 1.5 grams of fat, 19 grams of carbohydrate, and 25 grams of protein per serving. Participants in the experimental group will consume 3 servings per day.
Study NCT03454347 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower Limb Suspension
Description: This group will complete two weeks of lower limb suspension.
Study NCT03388827 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laminaria tent
Description: Laminaria tent was inserted for 12 hours before Hysteroscopy
Study NCT02524652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5% 20 mLs
Description: Injection of the local anesthetic at the end of surgery, either in the surgical sites by the surgeon, or in the adductor canal block by the anesthesiologist under ultrasound guidance.
Study NCT02524652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% 20 mLs
Description: Injection of the local anesthetic at the end of surgery, either in the surgical sites by the surgeon, or in the adductor canal block by the anesthesiologist under ultrasound guidance.
Study NCT05281783 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous radiofrequency ablation (RFA)
Description: We aim to evaluate the percutaneous radiofrequency ablation (RFA) efficacy as monotherapy in intermediate versus early-stage hepatocellular carcinoma (HCC).
Study NCT04436822 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring
Description: CGM and frequent sample testing
Study NCT02713230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine liposome injectable suspension
Description: 10 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 10 mL normal saline
Study NCT02713230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine liposome injectable suspension
Description: 20 mL EXPAREL (bupivacaine liposome injectable suspension)
Study NCT02713230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 mL normal saline as single-injection
Study NCT03388827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Laminaria plus Misoprostol
Description: Laminaria plus Misoprostol were inserted for 12 hours before Hysteroscopy
Study NCT02753972 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Eating and Living
Description: 8 week mindfulness skills intervention
Study NCT01419665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GP2013
Description: Type: Biological/Vaccine
Study NCT01419665 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: Type: Biological/Vaccine
Study NCT02065947 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: paravertebral block
Description: catheter with 3-level-injection
Study NCT02065947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl, propofol, atracurium
Description: endotracheal intubation
Study NCT02065947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine , adrenaline, ketamine bolus, midazolam
Description: a mixture of 10 ml bupivacaine 0.5% plus 20 ml lidocaine 2% with adrenaline 1:200,000, ketamine bolus 0.5 mg/kg, midazolam 2-3 mg and continuous propofol using target-controlled infusion (TCI) system aiming at effect site concentration (Ce) of 1-1.5 mcg/mL
Study NCT02065947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: catheter with 3-level-injection
Study NCT02753972 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Weight Loss Control
Description: 8 week active weight loss control group
Study NCT03439488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-440
Description: JNJ-440 will be administered as oral tablets in Parts 1, 2 and 3. JNJ-440 may be provided as oral solution in a cohort in Part 1.
Study NCT03439488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo as oral tablets will be administered in Parts 1, 2 and 3.
Study NCT01661673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-0962
Description: Arms: 1,2,3,4
Study NCT02065947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane and 50% oxygen in air
Study NCT01661673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Arm 5
Study NCT00246103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic acid
Description: Beginning Dose, Level 1: 15 mg/kg/day.
Study NCT00246103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Beginning Dose, Level 1: 75 mg/m\^2.
Study NCT00246103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: For breast cancer participants treated at MTD of Valproic acid and Epirubicin: 5-fluorouracil 500 mg/m\^2.
Study NCT00246103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide.
Description: For breast cancer participants treated at MTD of Valproic acid and Epirubicin: cyclophosphamide 500 mg/m\^2.
Study NCT03926013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63898081
Description: JNJ-63898081 will be administered.
Study NCT01678742 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-protein diet
Description: The high-protein diet is made up of 50% carbohydrate, 40% of protein and 10% of fat, providing 480 kcal.~A protein part of the high-protein diet is mostly composed of a grilled Jeju red horsehead fish, a special product of Jeju island in Korea.
Study NCT01678742 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard diet
Description: The standard diet is made up of 60% carbohydrate, 20% of protein and 20% of fat, providing 480 kcal.
Study NCT04236076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PulseHaler
Description: PulseHaler™ is a pulsating positive expiratory pressure ventilation device for treatment of COPD. PulseHaler™ is pre-programmed to deliver airflow at pre-defined frequencies, ranging from 3.5 Hertz (Hz) to 55Hz, and for pre-defined lengths of time.
Study NCT04236076 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham - control
Description: Sham device has the same look as PulseHaler and is set to deliver nominal pressure but it does not contain the active pulsating components.
Study NCT05585294 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Perturbation exercises: A new protocol of perturbation exercises aimed to disturb static and dynamic posture or equilibrium at primarily at body segments at hip and shoulder level were provided. The perturbation was initially started as anticipatory postural adjustment and progressed to compensatory postural adjustment, where stepping on various directions were challenged. The nature of perturbation or push or nudges applied by physiotherapists were progressed from a) self-generated to therapist applied, anticipated to unanticipated, stable to unstable platforms, static to dynamic postural tasks with loaded extremities and at higher level simple to higher cognitive tasks were also incorporated.